StockData

Bicycle Therapeutics vs Foghorn Therapeutics

BCYC and FHTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BCYC and FHTX compare

Bicycle Therapeutics is the larger company, worth 1.9 times as much as Foghorn Therapeutics ($236M against $123M).

Foghorn Therapeutics grew revenue faster over the last twelve months (357% versus 195% for Bicycle Therapeutics).

Foghorn Therapeutics keeps more of each dollar of sales as profit, with a net margin of 8.4% compared with −170% at Bicycle Therapeutics.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBCYCFHTX
Size and price
Market cap$236M$123M
Share price$3.37$2.07
Change, 1 year−48.6%−54.3%
Change, 5 years−94.2%−84.9%
Beta (5Y)1.371.87
Employees288106
StockData Score
Total score1111
Valuation score3 (better)2
Growth score22
Performance score22
Health score45 (better)
Dividend score00
Valuation
P/E–29.6×
P/S2.8×1.1× (better)
P/B0.5×–
EV/EBITDA–11.1×
FCF yield−74.9%−68.1% (better)
Fair value$16.02$2.09
Margin of safety79.0% (better)0.79%
Growth
Revenue growth (TTM)195%357% (better)
Revenue growth, 5Y average47.5%135% (better)
Profitability
Operating margin−189%2.1% (better)
Net margin−170%8.4% (better)
FCF margin−212%−74.6% (better)
Return on equity−25.2%–
Return on invested capital−4543%–
Financial health
Debt / equity0.00–
Interest coverage−815.6×–
Current ratio12.09 (better)4.24
Altman Z-score0.04 (better)−2.66
Piotroski F-score22
Dividends and buybacks
Dividend yield0.00%–
Years of dividend growth0–
Shareholder yield0.00%0.00%
Ownership
Held by institutions53.4%75.6%
Held by insiders21.3%36.3%
Insider net buying, 12 months−$523K–
Short interest, % of float–6.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.